#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Non-small cell lung cancer metastatic Type 2 diabetes mellitus More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Still's disease Mantle cell lymphoma stage II Mucopolysaccharidosis III Primary biliary cholangitis Erythema multiforme Iron overload Bronchiectasis Human papilloma virus immunisation Marginal zone lymphoma Peripheral primitive neuroectodermal tumour of soft tissue Lennox-Gastaut syndrome Extra-osseous Ewing's sarcoma Obliterative bronchiolitis Vernal keratoconjunctivitis Oesophageal squamous cell carcinoma stage II More trials…

    Learn about Rare Diseases

    Noonan syndrome – Diagnostics Mantle cell lymphoma stage II – Life with Disease Burkitt’s lymphoma Synovial sarcoma recurrent – Treatment Stevens-Johnson syndrome – Life with Disease Progressive multifocal leukoencephalopathy – Life with Disease Mucopolysaccharidosis II – Life with Disease Adrenogenital syndrome – Life with Disease Langerhans’ cell histiocytosis – Diagnostics Glomerulonephritis membranoproliferative – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    E2814 Festuca Elatior Pollen Extract Ng004 Luspatercept SALICYLIC ACID Rasagiline Celecoxib Tabelecleucel Vafidemstat Sapropterin Dihydrochloride Bi 3720931 Maribavir Abatacept Dabigatran Etexilate Ipatasertib Nitrous Oxide ZINC CHLORIDE Quemliclustat Masitinib SC0062 More therapies…

    Learn about Your Condition

    Autism spectrum disorder Pulmonary hypertension K-ras gene mutation Major depression Caesarean section Cervix carcinoma stage II Biotinidase deficiency Carotid arteriosclerosis Dystonic tremor Cryoglobulinaemia Subarachnoid haemorrhage Diabetic nephropathy Varices oesophageal Rectal cancer Primary amyloidosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Orszagos Onkologiai Intezet

Orszagos Onkologiai Intezet

Rkmt Ggbytp Upzd 7jca Ktmfkwrb Bnnzzdyzf 1jttt Hbcmopb

Want to learn more about this study or check if you can participate? Contact us.

  • Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma Patients Receiving JNJ-79635322 and Human Normal Immunoglobulin (IV)

    Recruiting

    2 1 1
    Investigated Drugs:
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    • Human Normal Immunoglobulin (Iv)
    • Tocilizumab
    France Greece Hungary Portugal Spain Sweden

  • Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

    Recruiting

    3 1 1
    Investigated Drugs:
    • [4-(METHYL-1H-PYRAZOL-4-YL)-BENZYL]-(6[7-(3-PYRROLIDIN-1-YL-PROPOXY)-IMIDAZO[1,2-A]PYRIDIN-3-YL]-PYRIMIDIN-4-YL]-AMINE
    • Imatinib Mesilate
    Finland France Germany Greece Hungary Italy +7

  • Rinatabart Sesutecan plus Bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
    • Bevacizumab
    Austria Belgium Czechia Denmark Finland France +6

  • Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Adagrasib
    • Cetuximab
    • Dexamethasone
    Belgium France Germany Greece Hungary Italy +5

  • A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

    Recruiting

    3 1
    Investigated Diseases:
    • Non-small cell lung cancer stage I
    Investigated Drugs:
    • Mrna-4157
    • Pembrolizumab
    France Germany Greece Hungary Italy The Netherlands +2

  • Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastric cancer
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Azd0901
    • Capecitabine
    • Fluorouracil
    Belgium France Germany Hungary Italy The Netherlands +2

  • Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Bulgaria Czechia Finland France +10

  • Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer metastatic
    • Fallopian tube cancer
    • Ovarian cancer
    Investigated Drugs:
    • LY4170156
    • Mirvetuximab Soravtansine
    • Bevacizumab
    Austria Belgium Czechia Denmark France Germany +9

  • Comparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • (R)-N-(4-([1,2,4]-TRIAZOLO[1,5-C]-PYRIMIDIN-7-YLOXY)-3-METHYLPHENYL)-5-((3,3-DIFLUORO-1-METHYLPIPERIDIN-4-YL)OXY)-6-METHOXYQUINAZOLIN-4-AMINE
    • Tucatinib
    • Trastuzumab
    Austria Belgium Czechia France Germany Hungary +5

  • A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.

    Recruiting

    3 1 1
    Investigated Diseases:
    • Pancreatic neuroendocrine tumour
    • Phaeochromocytoma
    • Bile duct cancer
    Investigated Drugs:
    • Belzutifan
    • Lenvatinib
    Belgium Czechia Denmark Finland France Germany +4
1 2 3 … 17
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!